| P50 | author | Thomas Jespersen | Q42703687 |
| | Jorgen K. Kanters | Q50884207 |
| | Jacob Tfelt-Hansen | Q54991182 |
| | Helena Carstensen | Q56191531 |
| | Rikke Buhl | Q56191533 |
| | Eva Zander Hesselkilde | Q57443197 |
| | Merle Friederike Fenner | Q58423830 |
| | Mette Flethøj | Q85670819 |
| | Stefan Sattler | Q86947798 |
| P2093 | author name string | Steen Pehrson | |
| | Ameli V Loft-Andersen | |
| P2860 | cites work | Recommendations for management of equine athletes with cardiovascular abnormalities | Q26853142 |
| | Reverse Use Dependence of Antiarrhythmic Class la, Ib, and Ic: Effects of Drugs on the Action Potential Duration? | Q28177913 |
| | Atrial flutter in patients treated for atrial fibrillation with propafenone | Q28336014 |
| | Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation | Q28360262 |
| | Electrocardiographic manifestations: ventricular tachycardia | Q30312174 |
| | Normal electrocardiographic QT interval in race-fit Standardbred horses at rest and its rate dependence during exercise. | Q33162409 |
| | 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society | Q34412804 |
| | Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation | Q34505579 |
| | Electrical, contractile and structural remodeling during atrial fibrillation | Q34682882 |
| | Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats | Q34721297 |
| | Electrophysiological effects of flecainide and propafenone on atrial fibrillation cycle and relation with arrhythmia termination | Q35373187 |
| | Torsade de pointes: the clinical considerations | Q35808897 |
| | Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man | Q36741131 |
| | Antiarrhythmic and electrophysiologic effects of flecainide on acutely induced atrial fibrillation in healthy horses. | Q36873774 |
| | Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode | Q37034727 |
| | Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia | Q37159637 |
| | Alpha-2 Agonists as Pain Therapy in Horses | Q37807712 |
| | Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil | Q43453208 |
| | Management of new onset atrial fibrillation | Q43719248 |
| | Use of intravenous flecainide in horses with naturally-occurring atrial fibrillation. | Q45174799 |
| | Use of propafenone for conversion of chronic atrial fibrillation in horses | Q46115043 |
| | Intravenous amiodarone treatment in horses with chronic atrial fibrillation | Q46502632 |
| | Effect of flecainide on atrial fibrillatory rate in a large animal model with induced atrial fibrillation. | Q47134767 |
| | Pharmacokinetics and electrophysiological effects of sotalol hydrochloride in horses. | Q48201149 |
| | Effects of an adapted intravenous amiodarone treatment protocol in horses with atrial fibrillation | Q49045361 |
| | Dual-chamber pacemaker implantation via the cephalic vein in healthy equids | Q49052241 |
| | Intracardiac overdrive pacing as a treatment of atrial flutter in a horse | Q49090850 |
| | Atrial and ventricular electrical and contractile remodeling and reverse remodeling owing to short-term pacing-induced atrial fibrillation in horses | Q49152226 |
| | Antiarrhythmic Effects of Combining Dofetilide and Ranolazine in a Model of Acutely Induced Atrial Fibrillation in Horses. | Q49183821 |
| | Cardiovascular effects of medetomidine, detomidine and xylazine in horses. | Q51372945 |
| | Antiarrhythmic agents: modulated receptor applications. | Q51794509 |
| | Pharmacologic inhibition of small-conductance calcium-activated potassium (SK) channels by NS8593 reveals atrial antiarrhythmic potential in horses. | Q54179198 |
| | Changes over time in echocardiographic measurements in young Standardbred racehorses undergoing training and racing and association with racing performance | Q58818025 |
| | Proarrhythmic effects of flecainide. Experimental evidence for increased susceptibility to reentrant arrhythmias | Q68004632 |
| | Factors affecting prognosis and conversion in equine atrial fibrillation | Q68023922 |
| | Supraventricular tachycardia mimicking ventricular tachycardia during flecainide treatment | Q70412437 |
| | Safe and efficacious dosage of flecainide acetate for treating equine atrial fibrillation | Q74180025 |
| | Time course of atrial fibrillation-induced cellular structural remodeling in atria of the goat | Q77326632 |
| | Torsade-de-pointes in a patient under flecainide treatment, an unusual case of proarrhythmicity | Q79286425 |
| | Treatment of chronic atrial fibrillation in the horse with flecainide: personal observation | Q80758288 |
| | Sudden death of a horse with supraventricular tachycardia following oral administration of flecainide acetate | Q85945685 |
| | Treatment of recent-onset atrial fibrillation with quinidine and flecainide in Thoroughbred racehorses: 107 cases (1987-2014) | Q88719110 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | atrial fibrillation | Q815819 |
| P304 | page(s) | 1708-1717 | |
| P577 | publication date | 2018-08-22 | |
| P1433 | published in | Journal of Veterinary Internal Medicine | Q15762439 |
| P1476 | title | Time-dependent antiarrhythmic effects of flecainide on induced atrial fibrillation in horses | |
| P478 | volume | 32 | |